2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
3
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Histologic Type
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Carcinoma
1
BRAF V600E Mutation
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
56
Cytarabine
43
fludarabine phosphate
37
Methotrexate
35
Whole-Body Irradiation
32
Mycophenolic Acid
29
Filgrastim
27
fludarabine
25
Peripheral Blood Stem Cell Transplantation
22
Vincristine
21
Cyclosporine
20
Busulfan
19
Dexamethasone
18
Specimen Handling
17
Methylprednisolone
17
venetoclax
16
Granulocyte Colony-Stimulating Factor
16
Tacrolimus
15
Hydrocortisone
15
Melphalan
14
Daunorubicin
14
Asparaginase
14
merphos
13
Thiotepa
13
Mercaptopurine
13
Leucovorin
13
Cord Blood Stem Cell Transplantation
13
Antilymphocyte Serum
13
Calcium Dobesilate
11
Biopsy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Biphenotypic, Acute
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA